Results of chemotherapy and antibody therapy in older patients
| Study . | Year . | Age . | Ph+ . | Patients (N) . | CR/CRi rate (%) . | Early death (%) . | Failure (%) . | CCR (%)∗ . | DFS/EFS (%)∗ . | OS (%)† . |
|---|---|---|---|---|---|---|---|---|---|---|
| Chemotherapy | ||||||||||
| Hunault-Berger et al109 | 2010 | |||||||||
| Arm 1 | 68 (55-77) | No | 31 | 90 | 7 | 3 | 32 (2 y) | n.r. | 35 (2 y) | |
| Arm 2 | 66 (60-80) | 29 | 72 | 10 | 17 | 52 (2 y) | 24 (2 y) | |||
| Goekbuget et al110 | 2012 | 57 (55-85) | No | 268 | 76 | 14 | 10 | 32 (5 y) | n.r. | 23 (5 y) |
| Fathi et al111 | 2016 | 58 (51-72) | Yes | 30 | 67 | 3 | 30 | n.r. | 52 (2 y) | 52 (2 y) |
| Ribera et al112 | 2016 | 66 (56-79) | No | 54 | 74 | 14 | 14 | n.r. | 24 (2 y)‡ | 30 (2 y)‡ |
| Kozlowski et al113,§ | 2017 | 69 (62-82) | Yes | 35 | 71 | 20 | 9 | n.r. | n.r. | 20 (3 y) |
| Kozlowski et al113,|| | 2017 | 63 (55-79) | Yes | 79 | 89 | 13 | n.r. | n.r. | n.r. | 39 (3 y) |
| Goekbuget et al104 | 2022 | 68 (56-86) | No | 841 | 73 | 14 | 13 | 37 (3 y) | n.r. | 28 (5 y) |
| Cohort 1 | 593 | 72 | 15 | 13 | 32 | |||||
| Cohort 2 | 248 | 75 | 9 | 16 | 50 | |||||
| Chemo-Immunotherapy | ||||||||||
| Stelljes et al114 InO chemo | 2022 | 64 (56-80) | No | 43 | 100 | 0 | 0 | n.r. | 73 (2 y) | 81 (2 y) |
| Chevallier et al115 InO chemo | 2022 | 68 (55-84) | No | 131 | 90 | n.r. | n.r. | n.r. | 50 (2 y) | 54 (2 y) |
| Goekbuget et al116 Chemo Blina | 2021 | 65 (56-76) | No | 34 | 83 | 7 | 10 | n.r. | 89 (1 y) | 84 (1 y) |
| Advani et al117 Blina mono | 2022 | 75 (66-84) | No | 29 | 66 | n.r. | n.r. | n.r. | 37 (3 y) | 37 (3 y) |
| Nasnas et al118 InO Blina chemo | 2022 | 68 (60-87) | No | 80 | 99 | 0 | 0 | n.r. | n.r. | 46 (5 y) |
| Study . | Year . | Age . | Ph+ . | Patients (N) . | CR/CRi rate (%) . | Early death (%) . | Failure (%) . | CCR (%)∗ . | DFS/EFS (%)∗ . | OS (%)† . |
|---|---|---|---|---|---|---|---|---|---|---|
| Chemotherapy | ||||||||||
| Hunault-Berger et al109 | 2010 | |||||||||
| Arm 1 | 68 (55-77) | No | 31 | 90 | 7 | 3 | 32 (2 y) | n.r. | 35 (2 y) | |
| Arm 2 | 66 (60-80) | 29 | 72 | 10 | 17 | 52 (2 y) | 24 (2 y) | |||
| Goekbuget et al110 | 2012 | 57 (55-85) | No | 268 | 76 | 14 | 10 | 32 (5 y) | n.r. | 23 (5 y) |
| Fathi et al111 | 2016 | 58 (51-72) | Yes | 30 | 67 | 3 | 30 | n.r. | 52 (2 y) | 52 (2 y) |
| Ribera et al112 | 2016 | 66 (56-79) | No | 54 | 74 | 14 | 14 | n.r. | 24 (2 y)‡ | 30 (2 y)‡ |
| Kozlowski et al113,§ | 2017 | 69 (62-82) | Yes | 35 | 71 | 20 | 9 | n.r. | n.r. | 20 (3 y) |
| Kozlowski et al113,|| | 2017 | 63 (55-79) | Yes | 79 | 89 | 13 | n.r. | n.r. | n.r. | 39 (3 y) |
| Goekbuget et al104 | 2022 | 68 (56-86) | No | 841 | 73 | 14 | 13 | 37 (3 y) | n.r. | 28 (5 y) |
| Cohort 1 | 593 | 72 | 15 | 13 | 32 | |||||
| Cohort 2 | 248 | 75 | 9 | 16 | 50 | |||||
| Chemo-Immunotherapy | ||||||||||
| Stelljes et al114 InO chemo | 2022 | 64 (56-80) | No | 43 | 100 | 0 | 0 | n.r. | 73 (2 y) | 81 (2 y) |
| Chevallier et al115 InO chemo | 2022 | 68 (55-84) | No | 131 | 90 | n.r. | n.r. | n.r. | 50 (2 y) | 54 (2 y) |
| Goekbuget et al116 Chemo Blina | 2021 | 65 (56-76) | No | 34 | 83 | 7 | 10 | n.r. | 89 (1 y) | 84 (1 y) |
| Advani et al117 Blina mono | 2022 | 75 (66-84) | No | 29 | 66 | n.r. | n.r. | n.r. | 37 (3 y) | 37 (3 y) |
| Nasnas et al118 InO Blina chemo | 2022 | 68 (60-87) | No | 80 | 99 | 0 | 0 | n.r. | n.r. | 46 (5 y) |
Arm 1, continuous infusion doxorubicin; Arm 2, pegylated doxorubicin; Cohort 1, original version of protocol; Cohort 2, more dose density, PEG-ASP consolidation, MRD-based Blina; CCR, continuous complete remission; CRi, complete remission with incomplete recovery; InO, inotuzumab ozogamicin; n.r., not reported; Ph+, Ph/BCR::ABL1 positive ALL included yes or no.
Median months or probability.
Probability.
Estimated from Kaplan-Meier curve.
EWALL protocol.
ABCVD protocol.